- Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting
- Nuvation Bio to Present at the Jefferies Global Healthcare Conference
- Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update
- Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Nuvation Bio Completes Acquisition of AnHeart Therapeutics
- Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer
- Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction
- Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors
More ▼
Key statistics
On Friday, Nuvation Bio Inc (NUVB:NYQ) closed at 2.77, -33.41% below its 52-week high of 4.16, set on Mar 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.86 |
---|---|
High | 2.87 |
Low | 2.73 |
Bid | 2.67 |
Offer | 3.14 |
Previous close | 2.91 |
Average volume | 1.78m |
---|---|
Shares outstanding | 247.17m |
Free float | 179.19m |
P/E (TTM) | -- |
Market cap | 645.12m USD |
EPS (TTM) | -0.3146 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 21:10 BST.
More ▼